Vol 22 No 1 (2016)

Vol 22 No 1 (2016)

Published May 5, 2016

Commentary

Anthony Johnson
An Impediment to Personalized Medicine Commercialization is the Lack of Understanding of the Value of the Testing
Requires Subscription or Fee PDF

Articles

Julia Schueler, Tobias Ostler
Biopharmaceutical Startup’s Need of a Regulatory Strategy
Requires Subscription or Fee PDF
Weifan Zhang, Rebecca Liu, Chris Chatwin
Marketing authorization of medical devices in China
Requires Subscription or Fee PDF
Demetris Iacovides
VC-backed Biotechnology Firms: What is Entrepreneurs’ Return?
Requires Subscription or Fee PDF
Elizabeth Ann McCaman
Encouraging Innovation in Preventive Health Technology: A Spotlight on Women's Health
Requires Subscription or Fee PDF
Kristina M Lybecker
Intellectual Property Protection for Biologics: Why the Trans-Pacific Partnership (TPP) Trade Agreement Fails to Deliver
Requires Subscription or Fee PDF
Thani Jambulingam, Carolin Schellhorn, Rajneesh Sharma
Using a Rasch Model to Rank Big Pharmaceutical Firms by Financial Performance
Requires Subscription or Fee PDF

Conference Report

Vasu Pestonjamasp
Moving from preclinical research to development
Requires Subscription or Fee PDF